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Background: Ganglioside GD2 is expressed on plasma membranes of various types of malignant cells. One of the
most promising approaches for cancer immunotherapy is the treatment with monoclonal antibodies recognizing
tumor-associated markers such as ganglioside GD2. It is considered that major mechanisms of anticancer activity of
anti-GD2 antibodies are complement-dependent cytotoxicity and/or antibody-mediated cellular cytotoxicity. At the
same time, several studies suggested that anti-GD2 antibodies are capable of direct induction of cell death of
number of tumor cell lines, but it has not been investigated in details. In this study we investigated the functional
role of ganglioside GD2 in the induction of cell death of multiple tumor cell lines by using GD2-specific monoclonal
antibodies.
Methods: Expression of GD2 on different tumor cell lines was analyzed by flow cytometry using anti-GD2
antibodies. By using HPTLC followed by densitometric analysis we measured the amount of ganglioside GD2
in total ganglioside fractions isolated from tumor cell lines. An MTT assay was performed to assess viability of
GD2-positive and -negative tumor cell lines treated with anti-GD2 mAbs. Cross-reactivity of anti-GD2 mAbs with
other gangliosides or other surface molecules was investigated by ELISA and flow cytometry. Inhibition of GD2
expression was achieved by using of inhibitor for ganglioside synthesis PDMP and/or siRNA for GM2/GD2 and
GD3 synthases.
Results: Anti-GD2 mAbs effectively induced non-classical cell death that combined features of both apoptosis
and necrosis in GD2-positive tumor cells and did not affect GD2-negative tumors. Anti-GD2 mAbs directly induced
cell death, which included alteration of mitochondrial membrane potential, induction of apoptotic volume decrease
and cell membrane permeability. This cytotoxic effect was mediated exclusively by specific binding of anti-GD2
antibodies with ganglioside GD2 but not with other molecules. Moreover, the level of GD2 expression correlated
with susceptibility of tumor cell lines to cytotoxic effect of anti-GD2 antibodies.
Conclusions: Results of this study demonstrate that anti-GD2 antibodies not only passively bind to the surface
of tumor cells but also directly induce rapid cell death after the incubation with GD2-positive tumor cells. These
results suggest a new role of GD2 as a receptor that actively transduces death signal in malignant cells.
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Tumor-associated gangliosides are very promising target
molecules for the development of new anti-cancer drugs.
Gangliosides are glycosilated lipid molecules belonging
to the class of glycosphingolipids and containing the sialic
acid residues in their carbohydrate structure. Quite a few* Correspondence: khol@mail.ru
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unless otherwise stated.gangliosides including GD2, GM2, GD3, NGcGM3 and
OAcGD2 are expressed at very high levels on the plasma
membrane of several tumor cells of neuroectodermal ori-
gin (such as neuroblastomas, melanomas, gliomas), as well
as on the cells of small cell lung cancers and lymphomas.
As a potential target molecule for anti-tumor therapy,
ganglioside GD2 has certain advantages when compared
to other tumor-associated gangliosides since this glyco-
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cells. Specifically, in normal non-malignant tissues, GD2
expression is mostly restricted to neurons, skin melano-
cytes and peripheral nerves. Moreover, on the surface of
normal cells, GD2 is a minor ganglioside, comprising
1-2% of total amount of gangliosides, and its level of
expression is 3-8-fold lower in comparison with other
tumor-associated gangliosides such as GD3 [1]. In tu-
mors the highest level of GD2 expression is observed
on the cell surface of almost all types of the primary
neuroblastomas reaching ~107 molecules per cell [2,3]. In
addition, GD2 is detected in about 75% of primary and
metastatic melanomas [4]. GD2 is also expressed in variety
of other tumors including bone and soft-tissue sarcomas,
small cell lung cancer, and brain tumors [5,6].
Today, one of the most promising approaches for
cancer immunotherapy is the treatment of cancer patients
with monoclonal antibodies (mAbs) directed against
tumor-associated molecules including ganglioside GD2.
Several monoclonal antibodies specific for the GD2 were
recently used in clinical trials [7]. The anti-GD2 mAbs
appear to act mainly through binding to the cell surface of
tumor cells and activation of complement system that
leads to complement-dependent lysis and/or antibody-
mediated cellular cytotoxicity that involve immune cells as
effectors [8]. At the same time, several studies suggested
that anti-GD2 mAbs may cause direct induction of cell
death in a number of tumor cell lines [9-11]. However it
has not been thoroughly investigated. The functional role
of GD2 ganglioside in this process has not been demon-
strated, and possibility of cross-reactivity of anti-GD2
mAbs with other gangliosides and glycosylated proteins
was not yet tested.
In this study we demonstrated a new role of ganglio-
side GD2 as a receptor for induction of non-classical cell
death of GD2-positive tumor cells of various origins. We
found that anti-GD2 antibodies specifically interacted
with GD2 resulting in direct induction of mitochondria-
dependent cell death. We also found that the level of
GD2 expression directly correlated with susceptibility of
these cells to cytotoxicity induced by anti-GD2 anti-
bodies. Thus, our study establishes a new role of GD2 as
a functionally active biomarker for anti-cancer therapy.
Methods
Cell lines and hybridomas
EL-4 (mouse lymphoma), L1210 (mouse lymphoma),
Jurkat (human lymphoma) cell lines were cultured in
RPMI-1640; IMR-32 (human neuroblastoma) and Neuro-
2A (mouse neuroblastoma) cell lines were cultured in
EMEM medium; human melanomas mS and A375 were
cultured in DMEM medium. All culture mediums were
supplemented with 10% heat-inactivated fetal bovine
serum (FBS, HyClone), 2 mM L-glutamine and antibiotic/antimycotic solution (Sigma). Hybridoma cells HB9326
were maintained in Hybri-Max RPMI-1640 medium,
supplemented with 10% FBS, 2 mM L-glutamine and anti-
biotic/antimycotic solution. All cell lines except mS were
kindly provided by Dr. E.V. Svirshchevskaya (Shemyakin-
Ovchinnikov Institute of Bioorganic Chemistry), cell line
mS was kindly provided by Dr. S.E. Dmitriev (Belozersky
Institute of Physico-Chemical Biology, Lomonosov Moscow
State University), HB9326 hybridoma cell line was originally
purchased from the American Type Culture Collection
(ATCC) and kindly provided by Dr. Telford (Experimental
Transplantation and Immunology Branch, NCI, National
Institutes of Health).
Antibodies and reagents
Mouse ME361 (S2A) antibody produced by HB9326
hybridoma cells were purified as described previously
[12]. GD2-specific antibodies ME361 were purified from
mouse ascites by affinity chromatography. Other anti-
GD2 14G2a mAbs were purchased from Millipore Inc.
Anti-GM2/GD2 synthase and anti-ALCAM antibodies,
siRNA and primers for GM2/GD2 and GD3 synthases
were purchased from Santa Cruz Biotechnology Inc.
Flow cytometry
Staining of EL-4, L1210, Jurkat, IMR-32, Neuro-2A, mS,
and A375 cells with two type of GD2-specific antibodies
14G2a and ME361 was performed as described previ-
ously [11]. In brief, cells were detached from the culture
plates (adherent cells were trypsinized and washed two
times with PBS) and were incubated with AlexaFluor-
488-labeled or unlabeled anti-GD2 mAbs (1 μg per 106
cells) for 1 h and then washed in PBS supplemented
with 1% FBS and 0.02% sodium azide. After that, in the
case of unlabeled anti-GD2 mAbs, the cells were incu-
bated with FITC-labeled anti-mouse IgG (1:1000) for
40 min, and then twice washed in PBS. All procedures
were performed at 4°C. The samples were immediately
analyzed using EPICS Coulter XL-MCL flow cytometer.
In each sample at least 5,000 events were collected. For
all samples, the analysis was performed in triplicate. The
data was analyzed using FlowJo and WinMDI software.
Microscopy and immunofluorescence
EL-4, IMR-32 and mS cell lines were grown on glass
coverslips (Fisher Scientific) placed into 6-well tissue
culture plates (Greiner). The cells that were grown to
80% confluence were subsequently washed with PBS and
fixed with 2% paraformaldehyde (PF) for 30 min at room
temperature (RT). After which, cells were washed twice
with PBS and quenched with 50 mM NH4Cl for 10 min.
After washing with PBS, the cells were blocked with PBS
containing 10% FBS and incubated with 100 μl anti-GD2
mAbs (10 μg/ml) for 1 h at 4°C and then with FITC-
Doronin et al. BMC Cancer 2014, 14:295 Page 3 of 17
http://www.biomedcentral.com/1471-2407/14/295labeled anti-mouse IgG (titer 1:1000) for 40 min at 4°C.
Stained cells were fixed with 2% PF for 30 min at RT,
and then sequentially washed in PBS and distilled water.
Counterstaining was performed with Hoechst 33342
(0.5 μg/ml) for 10 min, and finally cell preparations were
mounted in Mowiol (Calbiochem-Behring GmbH). Slides
were analyzed using a confocal laser scanning microscope
EZ-C1 Eclipse TE2000 (Nicon) equipped with a Plan Apo
40X and 60X objectives. Images were collected with
EZ-C1 program and processed with EC1 Viewer (Nikon).
Ganglioside purification and quantitation
Total cellular gangliosides were extracted from GD2-
positive (EL-4, mS, IMR-32) and GD2-negative (Jurkat,
L1210, A375, Neuro-2A) cell lines. Total lipid extracts
were obtained by multiple extractions of the lyophilized
cell pellets (5 × 107 cells) with chloroform/methanol (2:1
and 1:2 (v/v) at 4°C. At each stage, the hydrophobic
extracts were separated from the pellet by centrifugation
(12000 g, 10 min). Total lipid extracts were washed with
water five times to separate gangliosides as described by
Folch et al. [13]. Gangliosides in the aqueous phase were
further purified on the cartridge Strata-X (33 μm,
60 mg/3 ml; Phenomenex) and their concentrations
were assessed by the modified resorcinol method [14].
High-performance thin layer chromatography (HPTLC)
analysis of gangliosides was performed on silica gel using
60 HPTLC plates (Merck) in chloroform/methanol/0.2%
aq. CaCl2 (60:40:9, v/v/v) system. Then plates were dried
in the flow of cool air, incubated at 110°C for 15 s, and
visualized by spraying with resorcinol-HCl reagent and
further heating for 20 min at 110°C. Total cellular
ganglioside content was determined as the sum of indi-
vidual gangliosides measured by HPTLC densitometry
(Shimadzu CS-920) using known concentrations of bovine
liver GM1 (0.1 – 1 μg) as standard.
Viability and cell death assays
Propidium Iodide (PI) assay
Analyses of cell death as determined by DNA fragmenta-
tion were performed using propidium iodide (PI) stain-
ing in accordance to previously described method [15]
with modifications [16]. The tumor cells (5 × 105 cells
per sample) were incubated with anti-GD2 mAbs at con-
centration of 5 μg/ml for 24 h under standard culture
conditions. After incubation the cells were fixed and
permeabilized with ice cold ethanol at 4°C for 60 min,
and washed twice with PBS by centrifugation for 10 min
at 300 g. The cell pellets were resuspended in DNA
staining buffer (PBS, 20 μg/ml PI (Sigma), 20 μg/ml
RNase A (Fermentas)), and further incubated for 30 min
at RT. For all samples, cell death analysis was performed
in triplicate. An EPICS Coulter XL-MCL flow cytometer
was used to evaluate percent of cells with lower intensityof fluorescence in FL3 channel, which is characteristic of
cells with fragmented DNA. In each sample at least
5,000 events were registered. Data processing was per-
formed using FlowJo and WinMDI software.
MTT assay
Antibody-induced decrease in cell viability was analyzed
by colorimetric MTT (3-[[4,5]-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide; purchased from Sigma)
assay previously described by Denizot and Lang [17].
Briefly, tumor cells were cultured in 96-well flat-bottomed
tissue culture plates (104 cells/well, Greiner) with serial
dilutions of mAbs ME361 and 14G2a (concentration
range was from 0.031 to 10.000 μg/ml) for 72 h under
standard culture conditions. After incubation, the MTT
solution (250 μg/ml final concentration) was added to
each sample for 4 h. The optical density (OD) was read in
a Multiscan FC microplate reader (Thermo Scientific) at a
test wavelength of 540 nm. Cell viability was measured as
ratio of OD540 of cells treatment with anti-GD2 mAbs to
OD540 of control cells. All MTT experiments for each cell
line were reproduced at least three times.
Apoptotic volume decrease (AVD)
Apoptotic volume decrease of EL-4 cells was detected by
flow cytometry. Intact untreated cells or cells treated with
anti-GD2 antibodies were distinguished as normal and
shrunken populations by the changes in forward and side
light scatter (FCS/SSC) characteristics. Cells with apoptotic
volume decrease had reduced mean of forward scatter and
increased mean of side scatter as compared with normal
cells. In each sample at least 5,000 events were registered.
The data was analyzed using FlowJo and WinMDI software.
Caspase-3 activation assay
Evaluation of caspase-3 activation was performed in ac-
cordance with the method described earlier [18]. 2 × 106
of untreated or treated with anti-GD2 mAbs EL-4 cells
were washed once with PBS. Then, the cell lysate was
prepared using RIPA-buffer. 20 μl of the lysate was
placed in each well of a 96-well plate and the volume
was adjusted to 200 μl buffer (100 mM HEPES, 20%
glycerol, 5 mM DTT, 0.5 mM EDTA). The plate was
incubated for 30 min at +37°C and then solution of
fluorescently labeled caspase substrate Z-DEVD-AFC
(10 μM) was added to each well. The fluorescence inten-
sity was measured using Glomax spectrofluorometer
(Promega, USA) at wavelengths on excitation and emis-
sion 400 nm and 505 nm, respectively.
Plasma membrane permeability assay
The loss of plasma membrane integrity was analyzed using of
fluorescent DNA binding dye 7-AAD (7-aminoactinomycin
D; purchased from Sigma). EL-4 cells were washed once
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(PBS with 2 μg/ml 7-AAD). 7-AAD fluorescence of
cells was analyzed by flow cytometry using FL3-channel.
In each sample at least 5,000 events were collected.
The data was analyzed using FlowJo and WinMDI
software.
Assessment of mitochondrial membrane potential in
living cells
Mitochondrial membrane potential (ΔΨm) was mea-
sured using fluorescent dye 3,3′-dihexyloxacarbocyanine
iodide (DiOC6(3)) and 5,5′,6,6′-tetrachloro-1,1′,3,3′-tet-
raethylbenzimi-dazolylcarbocyanine iodide (JC-1) (Sigma).
The cell suspension was adjusted to a density of 1 × 106
cell/ml and incubated in complete medium for 15 min at
RT in the dark with 20 nM DiOC6(3) or with 2 μg/ml JC-1.
After which, the cells were washed twice in cold PBS, sus-
pended in a total volume of 500 μl and analyzed by flow
cytometry (FL1-channel for DiOC6(3), or FL1 and FL2
channels for JC-1). In each sample at least 5,000events
were collected. The data was analyzed using FlowJo and
WinMDI software.
ELISA
Polystyrene microtiter plates (Greiner) were coated with
gangliosides GD2, GM2, GD1b and GD3 that were
obtained according to the method applied in our previous
work [19], or kindly provided by Dr. Mikhalyov (Institute of
Bioorganic Chemistry, Russia Academy of Sciences) at
concentration 0.25 μg in 100 μl of 70% methanol per well.
Following air drying, all wells of the plate were blocked with
2% BSA in PBS-T (0.05% Tween 20 in PBS) in 100 μl per
well for 2 h at RT. Antibodies (100 μl per well in PBS-T)
were added in triplicates at different concentrations.
Following incubation for 2 h at 37°C and washing with
PBS-T, HRP-goat anti-mouse IgG (1:12000) were added.
After incubation for 1 h at 37°C and further washing,
TMB color reaction was performed and OD was read
using Multiscan FC microplate reader (Thermo Scientific)
at 450 nm. Percent of cross-reactivity was measured as
ratio of OD450 of TMB substrate in GM2-, GD1b- or
GD3-coated wells to OD450 of TMB substrate in GD2-
coated wells.
The amount of gangliosides adsorbed to each well was
determined by using fluorescent-labeled gangliosides
BODIPY-FL-C5-GM1 and BODIPY-FL-C5-GD3 (kindly
provided by Dr. Mikhalyov). Fluorescent probes were
coated at the same concentration as unlabeled ganglio-
sides (0.25 μg in 100 μl per well in 70% methanol), and
the same operations were performed for fluorescent
probes except adding of antibodies. At the last stage
BODIPY-labeled gangliosides GM1 and GD3 that were
adsorbed on surfaces of the wells were subsequently
dissolved in methanol and fluorescence was measuredusing a Dynatech Micro FLUOR Reader (excitation
490 nm, emission 510–570 nm). The amount of ganglio-
sides that were adsorbed on the wells was measured using
proper calibration curve (linear regression: RFU BODIPY-
FL-C5-GD3 = 20.726 + (271.329 × amount of ganglioside
per well), RFU BODIPY-FL-C5-GM1= 36.396 + (248.714 ×
amount of ganglioside per well, RFU – relative fluores-
cence units). All experiments were repeated three times.Modulation of GD2 expression
Downregulation of GD2 expression using PDMP
inhibitor
In the initial experiments we determined optimal con-
centration of PDMP inhibitor and time of incubation to
downregulate GD2 expression in EL-4 cells. EL-4 cells
were treated with different concentrations of PDMP (at
rage of 5–50 μM) for 2–7 days. The expression of GD2,
cell viability, and cell death were analyzed by flow cy-
tometry using surface staining for GD2, PI-, and MTT-
tests. In these experiments, the cells were treated with
2.5-100 μM PDMP and incubated for 72 h. After selec-
tion of optimal concentration, EL-4 cells were cultured
for 6 days in the presence of 15 μM PDMP before the
analysis of cytotoxicity induced by treatment with anti-
GD2 antibodies.Knockdown of GM2/GD2 and GD3 synthases by siRNA
siRNA for mouse GM2/GD2 or GD3 synthases were pur-
chased from Santa Cruz Inc. The cells were transfected
with these siRNAs using lipophilic agent Lipofectamine-
2000 (Invitrogen) according to the manufacturer’s instruc-
tions. Cells were harvested 48 h post-transfection and
further incubated with anti-GD2 mAbs for 24 h followed
by performing PI-test.Western blot analysis
Protein lysates of EL-4 cells were prepared using RIPA
buffer (Assay Design). The proteins from cell lysate were
fractionated in SDS-PAGE, and were transferred onto
nitrocellulose membranes using a semi-dry transfer
device V10-SDB (Biostep). Membranes were further in-
cubated in blocking buffer (0.05% Tween 20, 5% nonfat
dried milk in PBS) for 1 h at RT, followed by incubation
in primary anti-GM2/GD2 synthase antibody (10 μg/ml)
for 1 h at RT in PBS supplemented with 0.05% Tween
20 (PBS-T). After washing several times with PBS-T, the
membranes were incubated for 1 h in HRP-conjugated
secondary antibody (diluted 1:2000) at RT, and then
were washed four times with PBS-T. The immunoreac-
tive proteins were visualized using the Metal Enchanced
DAB Substrate Kit (Thermo Scientific) according to the
manufacturer’s instructions.
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Cells transfected with siRNA that target GM2/GD2
synthase or control cells were dissolved in 0.5 ml of
Trizol reagent for isolation of the total RNA as de-
scribed by the manufacturer (Invitrogen). All RNA ex-
tractions were carried out in a chemical hood using
RNAse-free labware. RNA quality and quantity were
evaluated by agarose gel electrophoresis and UV spec-
trometry (NanoVue, GE Helthscare). Samples were
stored at −80°C until used. For reverse transcription
reaction, 2 μg of total RNA was reversely transcribed
using MMLV-RT kits according to the manufacturer’s
protocol (Evrogen).
Real time RT-PCR
A ten-fold serial dilution of the cDNA derived from
EL-4 cells was prepared in order to make standard
curves and determination of PCR efficiency primers
for the GM2/GD2 synthase gene (Santa Cruz Biotech-
nology) and GAPDH housekeeping gene (Evrogen).
For performance of real-time RT-PCR we used a DT-
96 PCR machine (DNA-Technology LLC), and each
reaction was performed in a total volume of 20 μl
containing 2 μl of cDNA of the test sample or con-
trol sample (standard curve) with 5xSybrGreen-mix
prepared according to the manufacturer's protocol
(Eurogen). Final concentrations of the primer sets and
MgCl2 were 10 μM and 3 mM, respectively. After the
denaturation step at 95°C for 5 min, the amplification
program was set at 40 cycles each consisting of de-
naturation at 95°C for 15 s followed by annealing at
58°C for 10s, extension at 72°C for 3 min, followed
by detection at the specified acquisition temperature.
Melting curve analysis was used for amplicon`s size
estimation. Negative controls, samples without reverse
transcription or cDNA template were included with
every PCR run and were always negative (not shown).
Relative gene expression was determined as the ratio
of the GM2/GD2 synthase gene to the internal reference
gene expression (GAPDH) based on the Ct values using
QGENE software.
Statistical analysis
Graphs were created using SigmaPlot and MS Excel
software. These results were presented as Mean ± S.E.
of at least three independent experiments, or one rep-
resentative experiment of three was shown. Statistical
analysis was performed using Student's t-test, Mann–
Whitney Rank Sum Test, Analysis of Variance (ANOVA),
whereas differences between means were inspected
with Dunnett’s multiple comparison and Student-
Newman-Keuls multiple comparison post-hoc tests.
Significance levels of P < 0.05 were considered statisti-
cally reliable.Results
Selection of relevant GD2-positive and GD2-negative
tumor cell lines
We have analyzed the expression of ganglioside GD2 on
various tumor cell lines of different origin by performing
surface staining of the cells with anti-GD2 mAbs (not
shown). Based on these data, we selected three cell lines
with the highest expression level of GD2: mouse lymph-
oma EL-4, human neuroblastoma IMR-32, and human
melanoma mS; and three cell lines either without, or
with very low levels of GD2 expression: human Jurkat
lymphoma, mouse neuroblastoma Neuro-2A, human mel-
anoma A375. We have performed a surface staining of the
cells with anti-GD2 mAb 14G2a directly conjugated with
AlexaFluor488 and analyzed expression of GD2 by flow
cytometry. All three selected GD2-positive cell lines were
characterized by a high and uniform expression of
ganglioside GD2 on the cell surface (Figure 1), while
GD2-negative cell lines did not express GD2 as deter-
mined by flow cytometry (Additional file 1).
The representative histogram shown in Figure 1A
demonstrates an increase in mean fluorescence intensity
(MFI) of GD2 expression as determined by staining of
the cells with the anti-GD2 antibodies 14G2a when
compared to proper isotype control antibodies. These
results indicate that examined cell lines expressed GD2.
However, there was variability in MFI levels of GD2
expression among cell lines of different origin. The MFI
for GD2 on lymphoma EL-4 cells was 2.5 ± 0.3 fold
higher than that of melanoma mS cells, and was 2.7 ±
0.4 fold higher for neuroblastoma IMR-32 cells. Immu-
nofluorescence microscopy analysis showed a uniform
expression of GD2 on the surface of all three examined
GD2-positive tumor cell lines (Figure 1B). The similar
results were obtained when cells were staining with other
type of anti-GD2 mAb ME361 (not shown). Thus, we
have shown that the selected cell lines of different origin
were GD2-positive. All of these cell lines were charac-
terized by high expression level of ganglioside GD2
with the highest expression level in EL-4 lymphoma
cells. Flow cytometry and immunofluorescence mi-
croscopy analysis of GD2-negative cell lines confirmed
that ganglioside GD2 was not expressed in these cell
lines. (Additional file 1A and B).
Quantitative analysis of the total ganglioside and
ganglioside GD2 expression in the chosen GD2 positive
and GD2 negative cell lines
To determine the proportion of ganglioside GD2 con-
tent to the total ganglioside amount, densitometric
analysis was performed for ganglioside fractions isolated
by HPTLC from selected cell lines. As seen in Figure 2A,
the major gangliosides for EL-4 cells were GD2 and
GM2. The percentages of amount of ganglioside GD2 of
Figure 1 Expression of GD2 on the cell surface of EL-4, IMR-32, and mS tumor cell lines. Flow cytometry analysis of the cells stained with
anti-GD2 antibodies conjugated with AlexaFluor488 (14G2a antibodies; 5 μg/ml; see Methods) is shown in (A). Filled histograms (red color) show
staining with anti-GD2 mAbs, empty histograms – staining with an isotype control. Confocal imaging of EL-4, IMR-32, and mS cells stained with
anti-GD2 conjugated with AlexaFluor488 (14G2a antibodies; 5 μg/ml; see Methods) is shown in (B). The staining with anti-GD2 mAb is shown in
green color; the nuclei were counterstained with Hoechst 33342 (shown in blue). Bar scale: 50 μm.
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and mS were 60%, 45% and 35%, respectively (Figure 2B).
Ganglioside GD2 was not detected in ganglioside extracts
of Jurkat, Neuro-2A and A375 cell lines.
Thus, we confirmed biochemically that we chose
appropriate GD2-positive and GD2-negative cell lines to
study physiological effects of anti-GD2 mAbs.
Cytotoxic effects of two types of anti-GD2 mAbs 14G2a
and ME361 on GD2-positive and GD2-negative tumor cell
lines
The cytotoxic effects of anti-GD2 mAbs on selected
GD2-positive and GD2-negative cell lines were further
investigated using two different monoclonal antibodies14G2a and ME361. We found that after 24 h of incuba-
tion of tumor cells with anti-GD2 mAbs at concentra-
tion of 5 μg/ml GD2-positive cells underwent significant
morphological changes: shrinkage and rounding of the
cells, their detachment from plates, and formation of cell
aggregates. All of these morphological changes were the
most dramatic for GD2-positive EL-4 and mS cell lines
(Figure 3A). These anti-GD2 mAbs had no effect on
morphology of all examined GD2-negative cell lines
(Additional file 2A).
Next, we investigated DNA fragmentation in the popu-
lation of the cells treated with anti-GD2 mAbs. After
incubation with anti-GD2 antibodies, the cells were
fixed, permeabilized and stained with DNA-binding dye
Figure 2 Quantitative analysis of the total ganglioside content and proportion of ganglioside GD2. HPTLC analysis of individual gangliosides in
EL-4 cells was performed as described in Methods and shown in (A). Ratio of ganglioside GD2 to the total amount of gangliosides in the different tumor cell
lines is shown in (B). The total cellular ganglioside content was determined as the sum of individual gangliosides measured by HPTLC densitometry.
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hypodiploid peak of three tested GD2-positive tumor
cell lines EL-4, mS and IMR-32 was increased after anti-
GD2 treatment when compared to untreated cells.
After incubation with two different anti-GD2 antibodies
14G2a and ME361 at concentrations of 5 μg/ml the
percentage of EL-4 cells with fragmented DNA increased
5.0 ± 0.7 and 3.1 ± 0.9 fold above baseline level, respect-
ively (Figure 2B). When compared to EL-4 cells, an in-
crease in percentage of the cells with fragmented DNA for
IMR-32 and mS cell lines was slightly lower, but still sta-
tistically significant After incubation with 14G2a and
ME361 mAbs, the proportion of IMR-32 cells with frag-
mented DNA increased 2.5 ± 0.5 and 1.7 ± 0.4 fold, re-
spectively. For mS cells treated with 14G2a and ME361
antibodies, these values were 3.2 ± 0.4 and 2.3 ± 0.5, re-
spectively (Figure 3B). Anti-GD2 mAbs did not affect
GD2-negative tumor cell lines (Additional file 2B).
We further investigated the viability of tumor cells
incubated with various concentrations of anti-GD2 mAbs
using MTT assay. As shown in Figure 4, anti-GD2 anti-
bodies substantially decreased viability of GD2-positive
EL-4, mS and IMR-32 cell lines, without a significant
influence on GD2-negative cell lines Neuro-2A, A375,
and Jurkat. Note that the anti-GD2 antibodies 14G2a were
more cytotoxic for GD2-positive cell lines (Figure 4A)
when compared to ME361 antibodies (Figure 4B). After
72 h of incubation of the cells with the highest concentra-
tion of 14G2a antibodies (10 μg/ml), the strongest effect
was observed for EL-4 lymphoma cells, which express the
highest level of GD2. While the viability of the EL-4 cells
was reduced by more than 80%, the viability of mS andIMR-32 cells decreased by 60-70%. The cytotoxic effect of
ME361 antibodies was weaker, but still substantial, and
the differences in viability of GD2-positive and GD2-
negative cell lines were statistically significant for concen-
trations of antibodies higher than 2.5 μg/ml (Figure 4B).
In case of EL-4 and mS cell lines, the highest concen-
tration of ME361 antibodies of 10 μg/ml decreased the
viability of the cells by 60% and 40%, respectively.
These data indicate high level of cytotoxic effects of
anti-GD2 mAbs on tumor cells of different origins that
express GD2. On the other hand, anti-GD2 mAbs did
not influence on GD2-nevative cell lines. At the same
time, the cytotoxic activity of two different types of anti-
GD2 monoclonal antibodies was variable with the stron-
gest effect displayed by 14G2a antibodies. GD2-positive
cell lines varied in their susceptibility to cytotoxic effect
of anti-GD2 antibodies with the effect on EL-4 cells
being the strongest.
Anti-GD2 antibodies induce rapid cell death that
combined features of apoptosis and necrosis
We have chosen EL-4 cells and monoclonal antibody
14G2a as an optimal model to study mechanisms of cell
death induced by anti-GD2 mAb. We found that after
incubation of EL-4 cells with anti-GD2 mAb 14G2a
there was a significant increase in the proportion of the
cells with apoptotic volume decrease (AVD) (Figure 5A;
14G2a; gate R2) and the cells with permeable cell mem-
brane (Figure 5B; 14G2a). After 2 h of cell exposure to
anti-GD2 antibodies, 35 ± 6% of cells exhibited AVD
(Figure 5A; 14G2a; gate R2), and 40 ± 4% cells exhibited
permeability of cell membrane as determined by 7-AAD
Figure 3 The cytotoxic effects of two types of anti-GD2 antibodies on GD2-positive tumor cell lines. Phase-contrast images of GD2-positive
tumor cell lines EL-4, IMR-32, and mS after 24 h of incubation with or without anti-GD2 mAbs, 14G2a (5 μg/ml) and ME361 (5 μg/ml) are shown in (A). In (A),
bar scale: 50 μm. Analysis of DNA fragmentation (PI assay; see Methods) of GD2-positive tumor cells EL-4, IMR-32, mS treated with GD2 mAbs 14G2a (5 μg/ml)
and ME361 (5 μg/ml) is shown in (B). In (B), the percentages of the cells with fragmented DNA in hypodiploid peaks are shown for each histogram.
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only 4-8% of the cells with AVD were found in the
control untreated cells and only 3.5-7% of untreated cells
were 7-AAD-positive (Figure 5, control). We used staur-
osporine as positive control for cell death induction. The
effect of staurosporine was less dramatic than the effect
of antibodies: 7-10% of AVD cells (Figure 5A, stau-
rosporine; gate R2), and 8-11% of 7-AAD positive cells
(Figure 4B, staurosporine). Next we investigated activation
of caspase-3 in EL-4 cells treated for 24 h with anti-GD2antibody 14G2a using fluorescently labeled substrate for
caspase-3 Z-DEVD-AFC. We found that anti-GD2 anti-
bodies did not cause substantial activation of caspase-3:
the level of activity of this effector caspase was 3–4 folds
lower for anti-GD2-treated cells when compared to the
EL-4 cells treated with staurosporine (Figure 6A).
Pan-caspase inhibitor Z-VAD-FMK did not have any
significant effect on cell viability induced by anti-GD2
antibodies, but it did decrease (2.7-fold) the percentage of
apoptotic cells treated with staurosporine (Figure 6B).
Figure 4 Comparison of the influence of anti-GD2 antibodies
on viability of GD2-positive vs. GD2-negative tumor cell lines.
The viability of GD2-positive (EL-4, IMR-32, mS) and GD2-negative
(Neuro-2A, A375, Jurkat) tumor cells was assessed for the cells incubated
with various concentration of anti-GD2 mAbs for 72 h using MTT assay as
described in Methods. Results are shown for two monoclonal anti-GD2
antibodies 14G2a (A) and ME361 (B). Mean ± S.E. of three separate
experiments is shown, statistical analysis was performed using two-way
analysis of variance method for concentrations of 0.31 – 10 μg/ml (A),
and for concentrations 2.5 – 10 μg/ml (B). The differences between
GD2-positive and GD2-negative groups were statistically significant
(***, P < 0.001) as determined by Student-Newman-Keuls post-hoc analysis.
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cell death induced by anti-GD2 mAb using two specific sen-
sitive fluorescent probes JC-1 and DiOC6(3). Flow cytometry
analysis of mitochondrial membrane potential (MMP) of
AVD- and 7-AAD-negative EL-4 cells was performed and
the results are shown in Figure 6C, D. Using JC-1 and
DiOC6(3) probes, we found that treatment of cells with anti-
GD2 mAb 14G2a for 2 h resulted in a significant increase in
ΔΨm as determined by increased ratio of FL2/FL1 fluores-
cence for JC-1 (Figure 6C) and increase in MFI of green
fluorescence (FL1 channel) in 14G2a-treated cells for DiOC6
(3) (Figure 6D) when compared with ΔΨm of intact cells.
At the same time, staurosporine induced depolarization ofMMP in the AVD- and 7-AAD-negative cell populations
(Figure 6C and D). We found that there was a significant de-
crease in MMP in AVD- and 7-AAD-positive populations
when compared with AVD- and 7-AAD-negative popula-
tions of the cells treated with anti-GD2 mAb, staurosporine,
or untreated control cells (data not shown). Thus, we sug-
gested that the first event of anti-GD2 mAb-induced cell
death was a hyperpolarization of mitochondrial membrane
potential, and then AVD, cell membrane permeability and
decrease in MMP were occurred.
These results indicated that anti-GD2 mAb induced
non-classical mitochondria-dependent cell death with
the features of both apoptosis and necrosis and that
caspases did not play a pivotal role in this process.
Cross-reactivity of anti-GD2 mAbs with cell adhesion
molecule ALCAM and other gangliosides
There is an evidence that 14G2a antibodies could cross-
react with highly glycosylated ALCAM (CD166) adhesion
molecule [20], which is expressed in different tissues,
mainly on cells of the immune system, and this molecule
does not exhibit tumor association. In our experiments,
Western blot analysis showed that anti-GD2 antibodies
14G2a could bind to certain protein with a molecular
weight of 105–115 kDa from lysate of EL-4 cells. At the
same time anti-GD2 antibodies ME361 did not react with
any protein from the same EL-4 cell lysate (not shown).
Although 14G2a antibodies reacted with the protein
that has a molecular weight similar to ALCAM (100–
105 kDa), these results do not provide ultimate evidence
that 14G2 antibodies react with ALCAM, but not with
other proteins of the similar weight. Moreover, even if
such interaction of 14G2 antibodies with ALCAM is con-
firmed, it does not necessarily indicate that 14G2a mAb
specifically interacts with extracellular part of ALCAM
molecule. To assess the possibility of interaction of 14G2a
with extracellular part of ALCAM molecule, we have
selected several cell lines that expressed ALCAM and, at
the same time, were negative for GD2 (Figure 7).
Using specific antibodies that recognize extracellular
C-terminus of the ALCAM molecule we demonstrated that
GD2-positive cell line (EL-4) and two GD2-negative cell
lines (Jurkat and L1210) expressed ALCAM on their surface
(Figure 7A). At the same time, staining of Jurkat and L1210
cells with anti-GD2 antibodies 14G2a demonstrated that
these antibodies did not bind to these ALCAM positive cells
(Figure 7B). We concluded from these experiments that
14G2a antibodies did not bind the extracellular region of
ALCAM on the surface of ALCAM-positive cell lines.
Due to similar structure of various types of gangliosides, it
was also important to evaluate the ability of anti-GD2 mAbs
14G2a and ME361 to cross-react with other gangliosides.
We evaluated binding properties of both monoclonal anti-
bodies 14G2a and ME361 to immobilized gangliosides by
Figure 5 Analysis of apoptotic volume decrease and the loss of plasma membrane integrity for EL-4 lymphoma cells treated with anti-GD2
antibodies. Apoptotic volume decrease (AVD) (A) and cell membrane permeability (B) were analyzed for the control (untreated) EL-4 cells or after 2 h of
incubation with anti-GD2 mAbs 14G2a (5 μg/ml), or Staurosporine (500 nM) that was used as positive control for induction of apoptosis (see Methods). In (A),
R1 – region of viable cells, R2 – region of cells with AVD, and R3 – region of cell debris. In (B), percentages of 7-AAD positive cells are shown for each histogram.
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check amounts of gangliosides adsorbed to the plate to
ensure equal amount of gangliosides (0.3 ng/well) in each
well for further ELISA analysis (Additional file 3). This
assay allowed us to conduct a quantitative comparison of
binding patterns of anti-GD2 mAbs 14G2a and ME361 to
various gangliosides. Our analysis of cross-reactivity of
anti-GD2 mAbs is presented in Figure 8A, B. The ME361
antibody displayed a weak cross-reactivity with ganglioside
GD3 (14-17% of their binding to GD2) and GD1b (5-9%
of their binding to GD2) (Figure 8A), while 14G2a anti-
bodies showed no significant cross-reactivity with the
gangliosides GM2, GD1b and GD3 (Figure 8B). Conse-
quently, the cytotoxic effects of ME361 antibodies couldbe also mediated by interaction with not only GD2, but
also with gangliosides GD1b and GD3. However selected for
these experiments EL-4 cells did not have any detectable
levels of gangliosides GD3 or GD1b in the total ganglioside
content (Figure 2A). Flow cytometry analysis of EL-4 cells
stained with anti-GD3 mAb MB3.6 further confirmed that
GD3 is not expressed on the cell surface of these cells (not
shown). Since gangliosides GD3 and GD1b are not ex-
pressed on EL-4 cells, ME361 mAb could only bind to gan-
glioside GD2 on the surface of these cells to induce cell
death. Thus, our results indicate that two of our monoclonal
anti-GD2 antibodies, 14G2a and ME361, mediated cytotoxic
effect in EL-4 cells by interacting specifically with GD2 but
not with glycoproteins or other gangliosides.
Figure 6 Analysis of caspase-3 activation and mitochondria involvement during the cell death induced by anti-GD2 antibodies.
Enzymatic activity of caspase-3 in control (untreated) EL-4 cells, or treated with anti-GD2 mAbs 14G2a (5 μg/ml), or staurosporine (50 nM) for 24 h
is shown in (A). Mean ± S.E. of three separate experiments is shown. The statistical analysis was performed using two way analysis of variance
method. There was a statistically significant differences between groups (P≤ 0.001), *** P < 0.001 as determined by multiple comparisons of
experimental versus control groups using Dunnett's post-hoc analysis. Effect of Pan-caspase inhibitor Z-VAD-FMK (10 μM) on cell death induced
by anti-GD2 mAbs 14G2a (5 μg/ml) and Staurosporine (50 nM) after 24 h of incubation with EL-4 cells is shown in (B). Statistical analysis was performed using
Mann–Whitney rank sum test, the differences between control and pan-caspase inhibitor groups were statistically significant (*, P < 0.05; ***, P < 0.001). Effect
of anti-GD2 mAbs 14G2a (5 μg/ml) and staurosporine (50 nM) on ΔΨm of AVD-positive and 7AAD-negative populations of EL-4 cells. Representative density
plots of flow cytometry analysis of mitochonodrial potential (MPT) measured by using JC-1 probe (2 μg/ml) in intact versus the cells incubated with anti-GD2
mAbs 14G2a (5 μg/ml) or staurosporine (500 nM) for 2 h is shown. (C). Representative density plots of MPT measured by using DioC6(3) probe (20 nM) in
intact and cells incubated with anti-GD2 mAbs 14G2a (5 μg/ml) or staurosporine (500 nM) for 2 h is shown (D).
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of the cells to anti-GD2 mediated cell death
One of the experimental approaches to reduce of GD2
expression on the cell surface is the usage of the common
ganglioside biosynthesis inhibitor PDMP. In the first series of
experiments, we determined the optimal concentration of
PDMP in order to effectively inhibit ganglioside expression in
EL-4 cells without affecting cell viability. The viability and cell
death of EL-4 cells treated with PDMP was assessed using
MTT- and PI-assays, respectively. We found that 15 μM was
the optimal concentration for PDMP that did not affect via-
bility of the EL-4 cells (Figure 9A) and did not induce cell
death (not shown). At the optimal concentration of PDMP
(15 μM), the level of GD2 expression was reduced by 75%
when compared to untreated cells (Figure 9B; PDMP).
Another approach to inhibit the biosynthesis of gan-
glioside GD2 was a transfection of EL-4 cells with siRNA
that target GM2/GD2 and GD3 synthases. Transfection
of the cells with siRNA for GM2/GD2 synthase resulted
in substantial decrease in expression of this enzyme on
the mRNA (Figure 9C) and protein (Figure 9D) levels.
As shown in Figure 8B, the transfection of the cells with
siRNA for GM2/GD2 synthase resulted in ~60% de-
crease in GD2 expression on the surface of EL-4 cells.
Transfection of the cells with siRNA for GD3 synthaseresulted to 50-55% decrease in GD2 surface expression
level (Figure 9B). Cotransfection of EL-4 cells with two
siRNAs for both GM2/GD2 and GD3 synthases did not
lead to further decrease in GD2 level. In addition, combin-
ation of treatment of EL-4 cells with PDMP and transfec-
tion with siRNA for GM2/GD2, or GD3 synthase, did not
result in robust decrease in GD2 level when compared
with PDMP treatment alone (Figure 9B). This complex
treatment with siRNA and PDMP induced significant lost of
viability of EL-4 cells (not shown). Therefore, for compara-
tive analysis of cytotoxic effects of anti-GD2 mAb on cells
with normal and inhibited GD2 expression, we used cells
treated with PDMP or transfection with siRNA for GM2/
GD2 synthase, because these treatments were effective for
decrease in GD2 level without affecting cell viability.
Using the PI assay we have demonstrated that EL-4
cells with inhibited biosynthesis of ganglioside GD2 were
significantly less susceptible to cell death induced by
anti-GD2 mAbs. Cells treated with PDMP became irre-
sponsive to anti-GD2 mAbs, while knockdown of GM2/
GD2 synthase decreased the percentage of cells with
fragmented DNA by ~60% (Figure 9E). These results
indicate that susceptibility of the cells to cell death in-
duced by anti-GD2 antibodies directly correlated with
the level of GD2 expression at the cell surface.
Figure 7 Cross-reactivity of anti-GD2 antibodies with ALCAM adhesion molecule. Flow cytometry analysis of EL-4, Jurkat and L1210 cells
stained with anti-ALCAM (С20) antibodies is shown in (A), and staining with anti-GD2 14G2a antibodies is shown in (B) . In (A, B) filled histograms
show staining with anti-GD2 mAbs, empty histograms – staining with secondary control antibodies.
Figure 8 Cross-reactivity of anti-GD2 antibodies with gangliosides GM1, GM2, GD1b and GD3. (A, B) Interaction of anti-GD2 antibodies
with gangliosides GD2 vs. GM1, GM2, GD1b and GD3 was assessed by ELISA as described in Methods. Plates were coated with gangliosides GD2,
GM1, GM2, GD1b, and GD3 (0.25 μg/well) and incubated with two types of anti-GD2 mAbs (0.156 - 10 μg/ml) ME361 (A) and 14G2a (B). In (A),
the level of cross-reactivity is presented as the ratio for GM2, GD1b and GD3 binding to that of GD2. Mean ± S.E. of three separate experiments
are shown, statistical analysis was performed using two-way analysis of variance method. There was a statistically significant difference between
groups (P≤ 0.001), ***P <0.001 as determined by multiple comparisons versus zero cross-reactivity by Dunnett's post-hoc analysis (A). In (B),
multiple comparisons were not performed, since the values of the cross-reactivity were less than 2%.
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Figure 9 Analysis of susceptibility of EL-4 cells with down-modulated GD2 to cell death induced by anti-GD2 antibodies. Cell viability
(MTT assay, see Methods) of EL-4 cells treated with various concentrations of PDMP (2.5-100 μM) is shown in (A). Flow cytometry analysis of GD2
expression in the control cells vs. the cells with inhibited GD2 biosynthesis (with PDMP or siRNA GM2/GD2 synthase) is shown as the ratio of MFI
of cells with reduced GD2 expression to MFI of control cells (B). The expression of GM2/GD2 synthase on mRNA level is shown in (C). The expression
of GM2/GD2 synthase on a protein level in EL-4 cells transfected with siRNA that target GM2/GD2 synthase is shown in (D). Cytotoxic effects of
anti-GD2 mAb 14G2a (5 μg/ml) on control EL-4 cells vs. cells with inhibited GD2 expression is shown in (E). In (C), RNA from control cells and cells
transfected with GM2/GD2 synthase siRNA was isolated, and the expression of mRNA for GM2/GD2 synthase was determined by real time RT-PCR as
described in Methods. In (D), expression of GM2/GD2 synthase was analyzed by Western blot as described in Methods. In (E), cytotoxicity was analyzed
by PI assay as described in Methods.
Doronin et al. BMC Cancer 2014, 14:295 Page 13 of 17
http://www.biomedcentral.com/1471-2407/14/295Discussion
In this study we demonstrated for the first time a func-
tional role of anti-GD2 antibodies as direct inducers of
cells death due to specific binding of these antibodies to
GD2. The role of anti-GD2 antibodies has never been
examined systematically because of certain technical
limitations. In previous publications a limited number oftumor cell lines were used and anti-GD2 antibodies of
various origin and broad specificity were utilized that
could react not only with GD2 but also with number of
other glycoproteins and glycolipids. Therefore it was not
known whether GD2 is a single functional molecule that
induces cytotoxic signal or other molecules are involved
in this process. This fact is especially important, because
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ited cross-reactivity with other structurally similar
gangliosides [21], as well as with several cell adhesion
molecules [20,22].
In a number of studies it was shown that antibodies
against various tumor-associated gangliosides have
tendency to induce or enhance the tumor cells death
[9,11,23-25]. It is worth noting that Fab-fragments of
these antibodies retain the functional activity of whole
molecules to induce the cell death, and thus the cross-
linking of gangliosides on the cell surface by the whole
antibody molecules (or interaction with immune cells or
complement via Fc-fragments) is not essential for the
induction of cell death [12,26]. This fact suggests that
gangliosides may have the ability to accept and trans-
duce the signals of the death inside the cell. However,
glycosphingolipids, particularly gangliosides, do not be-
long to classical death receptors (e.g. CD95) since they
are lipid, not protein molecules, and lack the classic
transmembrane domain capable of signal transduction.
However, gangliosides could serve as the target mole-
cules for a number of ligands due to their specific
localization in the outer monolayer of plasma membrane
and due to the presence of branched sialylated carbo-
hydrate chains exposed at the extracellular space. For
example, the ganglioside GM1 specifically binds cholera
toxin B-subunit [27], and gangliosides GD1a, GD1b,
GT1b bind tetanus and botulinum toxins [28,29]. But in
these cases, gangliosides are considered to be just pas-
sive binding receptors that do not transduce signal
inside the cell. On the other hand, gangliosides were
found to be involved in cell death processes such as
apoptosis. It was demonstrated that intracellular level of
the ganglioside GD3 is increased during progression of
apoptotic signal induced through CD95, and inhibition
of GD3-synthase leads to reduction of the apoptosis
[30]. In several instances it was reported that ganglio-
sides may act as not only modulators but also inducers
of cell death. For example, exogenous monosialic gangli-
osides induced apoptosis in CD8 T cells, which was
considered to be one of the major mechanisms of
immune suppression mediated by the tumor-associated
gangliosides [31].
As the functions of gangliosides in regulation of cell
death and the importance of GD2 as a target molecule
for antibody-based anti-cancer therapy are not well
defined, we believe that it is important to evaluate the
role of GD2 in the reception and transduction of the
cytotoxic signal. For this purpose, we used two different
monoclonal antibodies against ganglioside GD2. Using
anti-GD2 antibodies ME361 and 14G2a, we showed that
these antibodies specific for ganglioside GD2 could
induce strong cytotoxic effects on tumor cells of different
origins. We established a number of common features ofeffects anti-GD2 mAbs on various tumor cell types. First,
cytotoxic effects of the antibodies were observed only for
GD2-positive cells. Second, the strongest cytotoxic effects
were observed in the case of EL-4 lymphoma, which is
characterized by the highest level of GD2 expression in
comparison with other cell lines. Third, both anti-GD2
mAbs 14G2a and ME361 substantially decreased viability
of EL-4, mS and IMR-32 cell lines in a dose-dependent
manner. Thus, these results confirm the involvement of
ganglioside GD2 in the reception and transduction of
cytotoxic signal.
As we mentioned above, the studying of functional
role of gangliosides such as GD2 is challenging due to
cross-reactivity of anti-GD2 mAbs with a number of
glycosylated proteins and other glycosphingolipids with
a similar structure of the carbohydrate chains [20,32].
For example, gangliosides GD3 and GD1b have rather
similar structures. In addition, a sialylated adhesion mol-
ecule NCAM has the same type of sialic acid linkages as
ganglioside GD2. In the study by Patel et al. [22] it was
suggested that anti-GD2 monoclonal antibody 3 F8
recognizes not only GD2 but also NCAM. Furthermore,
the same binding sites for anti-GD2 mAbs may be
present on other glycoproteins that do not have the
structural similarity with GD2. It was shown that the
anti-GD2 mAb 14G2a could interact with another adhe-
sion molecule ALCAM, which is structurally similar to
NCAM [20]. On the other hand, reported interactions of
anti-GD2 antibodies with ALCAM and/or NCAM is
debatable since it was not confirmed by other resear-
chers [33,34]. In view of these conflicting results, we
conducted series of experiments to examine possible
cross-reactivity anti-GD2 mAbs with other molecules
structurally related to GD2 and also expressed in tumor
cells. In these experiments we have shown that ME361
did not bind to any proteins from whole cell lysate of
EL-4 cells, while 14G2a could bind to the protein of a
molecular weight of 105–110 kDa, which is consistent
with results published by Kozber et al. [20]. However,
the results of our flow cytometry analysis of reactivity of
14G2a mAbs with GD2-negative/ALCAM-positive cell
lines have shown that although cross-reactivity of 14G2a
with ALCAM was obvious as determined by Western
blot analysis. However, we found that the binding site of
the protein exposed to the antibodies in Western blot is
not located on the extracellular portion of ALCAM
molecule as determined by FACS. Therefore, ALCAM
does not play a significant role for death signal transduc-
tion triggered by anti-GD2 mAb 14G2a. In our study of
cross-reactivity of anti-GD2 mAbs with other ganglio-
sides, we found that ME361, which exhibit high affinity
to ganglioside GD2, could bind gangliosides GD1b and
GD3. For 14G2a antibodies, the cross-reactivity with
other gangliosides was not detected. We found that EL-4
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Since the gangliosides GD3 and GD1b are absent in the
cell membrane of EL-4 cells, the anti-GD2 mAb ME361
could only interact with ganglioside GD2, and cross-
reactivity of these antibodies with other gangliosides did
not contribute to observed cytotoxic effect of these anti-
bodies. Thus, our results point out the predominant role
of GD2 in the reception of cytotoxic signals induced by
two types of anti-GD2 antibodies.
To further prove the exclusive role of ganglioside GD2
in a reception of cytotoxic signal, we reduced the expres-
sion level of GD2 on the surface of EL-4 tumor cell line,
and these cells with decreased expression of GD2 were
used to study cytotoxic effects of anti-GD2 mAbs. Com-
parison of the efficiency of anti-GD2-mAb-induced cyto-
toxic effects in intact cells versus cells with reduced
expression of GD2 allowed us to directly assess the con-
tribution of this ganglioside in induction of cell death.
Inhibition of the enzymes responsible for the ganglioside
synthesis let us to obtain the cells with significantly
reduced expression of GD2. The cytotoxic effect caused
by anti-GD2 mAbs was much higher for intact cells than
for cells with inhibited expression of GD2. Thus, we
demonstrated that ganglioside GD2 itself could serve as a
receptor of cell death in GD2-positive tumor cells.
However, several important questions remain unclear:
1) how does the GD2 transmit a cell death signal inside
the cell; 2) what causes the variability in efficiency of the
cytotoxic effect induced by the different anti-GD2 mAbs;
3) whether the property of GD2 molecule being a recep-
tor of death signal is a general feature of other tumor-
associated gangliosides?
The published reports regarding the role of ganglio-
sides in regulation of cell death are rather conflicting
and contradictory. The researchers have incoherent
points of view about the mechanisms of the cytotoxic
action of antibodies to the tumor-associated ganglio-
sides. Thus, a number of researchers have observed cer-
tain aspects of apoptotic cell death (e.g. activation of
caspases and other typical characteristics of classic apop-
tosis) in the cells exposed to the GD2- and NeuAcGD2-
specific antibodies [10,25,35]. On the other hand, it was
shown that antibodies to tumor-associated ganglioside
NeuGcGM3 induced cell death by mechanism of necrosis
with formation of the membrane pores. The researchers
showed that this process is caspase-independent [24,36].
Such results could be explained by both the different
origin of tumor cell lines used in these studies, and by
targeting different tumor-associated gangliosides. Also it
was reported that caspases did not play a key role and did
not determine the mechanism of cell death triggered by
anti-GD2 mAbs [37]. According to this study, cell death
signaling pathways triggered by anti-GD2 mAbs are com-
plex and could be attributed to non-classical mechanismsof cell death, with features of apoptosis (e.g. AVD) and
necrosis (e.g. plasma membrane permeability), and with
involvement of mitochondria-dependent pathways.
We assume that one of the mechanisms of the observed
process induced by anti-GD2 mAb is the translocation of
ganglioside GD2 from cell membrane into intracellular
compartments that leads to change in intracellular traffic
resulting in mitochondria damage. As shown in our study,
the anti-GD2 mAb induced rapid hyperpolarization of
mitochondrial membrane potential. We also detected
rapid internalization of the complexes of anti-GD2 mAbs
with ganglioside GD2 across the cell membrane inside the
cell. For 14G2a antibodies this process was more effective
compared to ME361 mAbs (unpublished observation). On
the other hand, it is known that induction of cell death
through classic death receptors such as Fas/CD95 or
TNFR results in changing of the intracellular traffic and/
or biosynthesis of GD3, a ganglioside structurally similar
to GD2, leading to translocation of GD3 into the mito-
chondria and to direct induction of cell death in a
mitochondria-dependent manner [30,38]. We suggest that
binding of anti-GD2 mAbs with GD2 on a cell surface
could lead to translocation of this ganglioside into mito-
chondria and induction of cell death in a manner similar
to GD3.
Thus, our study suggests new mechanisms of direct
cytotoxic action of ganglioside-specific antibodies, which
are different from classical apoptosis and require further
investigation.Conclusions
We provided evidence for the new functional activity of
GD2 ganglioside as a receptor for cell death signal. Since
GD2 is a promising target of anti-cancer therapy, the
observed effector properties of GD2 as a receptor and
transducer of death signal could be used for the develop-
ment of new types of anti-cancer drugs.Additional files
Additional file 1: Expression of GD2 on the cell surface of Jurkat,
Neuro-2a, and A375 tumor cell lines. Flow cytometry analysis of the
cells stained with anti-GD2 antibodies conjugated with AlexaFluor488
(14G2a antibodies; 5 μg/ml; see Methods) is shown in (A). Filled histograms
(red color) show staining with anti-GD2 mAbs, empty histograms – staining
with an isotype control. Confocal imaging of Jurkat, Neuro-2a, and A375
cells stained with anti-GD2 conjugated with AlexaFluor488 (14G2a
antibodies; 5 μg/ml; see Methods) is shown in (B). The nuclei were
counterstained with Hoechst 33342 (shown in blue). In (B), bar scale: 50 μm.
Additional file 2: The cytotoxic effects of anti-GD2 antibodies on
GD2-negative tumor cell lines. Phase-contrast images of GD2-negative
tumor cell lines Jurkat, Neuro-2a, and A375 after 24 h of incubation with
or without anti-GD2 mAbs, 14G2a (5 μg/ml) and ME361 (5 μg/ml) are
shown in (A). Analysis of DNA fragmentation (PI assay; see Methods) of
GD2-negative tumor cell lines Jurkat, Neuro-2a, and A375 treated with
GD2 mAbs 14G2a (5 μg/ml) and ME361 (5 μg/ml) is shown in (B). In (A),
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in hypodiploid peaks are shown for each histogram.
Additional file 3: Quantitative analysis of the gangliosides
adsorbed on the ELISA plates. (A) The RFU (relative fluorescence
units) level of fluorescent-labeled gangliosides BODIPY-FL-C5-GM1 and
BODIPY-FL-C5-GD3 bound to the well before TMB reaction development in
ELISA experiments is shown. Mean± S.E. of nine separate experiments is shown.
The RFU level was measured at 490 nm. The amount of BODIPY-FL-C5-GM1
bound to the well = 0.29 ± 0.04 ng, BODIPY-FL-C5-GD3 = 0.34 ± 0.05 ng
which was measured using calibration curve. Statistical analysis was
performed using Student’s t-test, there was not a statistically significant
difference between BODIPY-FL-C5-GD3 and BODIPY-FL-C5-GM1groups
(P = 0.765). (B) Calibration curve of fluorescent-labeled gangliosides
BODIPY-FL-C5-GM1 and BODIPY-FL-C5-GD3 is shown, Linear regression: RFU
BODIPY-FL-C5-GD3 = 20.726 + (271.329 × Amount of ganglioside per well),
RFU BODIPY-FL-C5-GM1 = 36.396 + (248.714 × Amount of ganglioside per
well, RFU - relative fluorescence units). Titration points are shown as Mean± S.E
of nine experiments. Statistical analysis was performed using Mann–Whitney
rank sum test, there was no statistically significant difference between
BODIPY-FL-C5-GD3 and BODIPY-FL-C5-GM1 (P = 0.911; not significant).
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